SAN FRANCISCO--(BUSINESS WIRE)--Dec. 16, 2015--
Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an
animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, and high-value horses, announced today the appointment of Karen
Wright as chief financial officer, effective immediately. John Kallassy,
Jaguar’s former CFO, will continue to serve the Company as chief
operating officer. Mr. Kallassy will assist with the transition of the
CFO role.
Karen Wright brings more than 30 years of financial experience with a
number of international biotech companies. Wright was most recently head
of finance for Clene Nanomedicine. She also served as vice president of
finance and corporate controller at multiple other private and public
companies, including Veracyte (NasdaqGM: VCYT) and Intermune, which was
acquired by Roche. Early in her career, Wright spent 13 years at
Genentech building a strong foundation in the biotech industry.
“We are excited to welcome Karen to the Jaguar team. With more than 30
years of senior executive experience in life science companies, her
addition strengthens our leadership team as we look to expand our
clinical and commercial activities,” said Lisa Conte, Jaguar’s president
and CEO. “Karen has proven herself to be a skilled financial leader by
helping multiple companies analyze and streamline their financial
operations, develop new strategies, and implement new systems, processes
and controls needed to scale-up the businesses.”
“We are very thankful for John’s financial leadership during Jaguar’s
IPO and through our first three quarters as a public company. He is an
integral member of our executive team,” added Conte.
Karen Wright stated, “I am honored to join such a capable and
experienced management team and become part of a company whose products
are at the forefront of innovation in the animal health space.”
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, and high-value horses. Canalevia™
is Jaguar’s lead prescription drug product candidate for the treatment
of various forms of diarrhea in dogs. Canalevia™ is a
canine-specific formulation of crofelemer, an active pharmaceutical
ingredient isolated and purified from the Croton lechleri tree,
which is sustainably harvested. Neonorm™ Calf and Neonorm™
Foal are the Company’s lead non-drug products. Neonorm™ is a
standardized botanical extract derived from the Croton lechleri
tree. Canalevia™ and Neonorm™ are distinct
products that act at the same last step in a physiological pathway
generally present in mammals. Jaguar has nine active investigational new
animal drug applications, or INADs, filed with the FDA and intends to
develop species-specific formulations of Neonorm™ in six
additional target species, and formulations of Canalevia™ for
cats, horses and dogs.
For more information, please visit www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the Company’s intention
to develop species-specific formulations of Neonorm™ in
additional target species, and the Company’s plan to develop
formulations of Canalevia™ for cats, horses and dogs. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms or
other similar expressions. The forward-looking statements in this
release are only predictions. Jaguar has based these forward-looking
statements largely on its current expectations and projections about
future events. These forward-looking statements speak only as of the
date of this release and are subject to a number of risks, uncertainties
and assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of any
new information, future events, changed circumstances or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151216006270/en/
Source: Jaguar Animal Health, Inc.
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
Allison
Soss, 212-896-1267
asoss@kcsa.com
